Sheena Brown
Psychiatric/Mental Health · Baton Rouge, LANPI 1932811437
Payments from drug & device makers
Across 206 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$570
- Alkermes, Inc.$474
- Neurocrine Biosciences, Inc.$470
- AbbVie$416
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$382
- Lundbeck LLC$273
- plus $1K from 11 others
What the payments were for
- Food & beverage$3,775100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 30 | $570 |
| Alkermes, Inc. | 27 | $474 |
| Neurocrine Biosciences, Inc. | 19 | $470 |
| AbbVie | 27 | $416 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $382 |
| Lundbeck LLC | 21 | $273 |
| Otsuka America Pharmaceutical, Inc. | 13 | $241 |
| Johnson & Johnson | 13 | $197 |
| Teva Pharmaceuticals USA, Inc. | 6 | $147 |
| Sage Therapeutics, LLC | 6 | $118 |
| Axsome Therapeutics, Inc. | 4 | $113 |
| Vanda Pharmaceuticals Inc. | 3 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $101 |
| Almatica Pharma LLC | 4 | $94 |
| Braeburn Inc. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
$3,775 in reported general payments places this provider in the 75th percentile of 615 psychiatric/mental health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 14 | $35,612 |
| Trazodone Hcl | 69 | $1,291 |
| Oxcarbazepine | 25 | $877 |
| Buspirone Hcl | 40 | $714 |
| Lurasidone Hcl | 16 | $635 |
| Aripiprazole | 14 | $568 |
| Risperidone | 65 | $551 |
| Olanzapine | 40 | $462 |
| Divalproex Sodium | 20 | $404 |
| Quetiapine Fumarate | 29 | $364 |
| Benztropine Mesylate | 28 | $304 |
| Bupropion XlBupropion Hcl | 22 | $274 |
| Escitalopram Oxalate | 40 | $259 |
| Lithium Carbonate ErLithium Carbonate | 16 | $216 |
| Lithium Carbonate | 22 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $197 | $35,61214 claims |
| Almatica Pharma LLCSertraline Hcl | $94 | $13429 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Baton Rouge
- Amy LacoutureBaton Rouge$663K
- Yolanda CockerhamBaton Rouge$11K
- Drew DykesBaton Rouge$11K
- Tiffany JordanBaton Rouge$10K
- Elizabeth CasselberryBaton Rouge$9K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.